Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults

BACKGROUND AND OBJECTIVES: Osilodrostat (LCI699) is an adrenal steroidogenesis inhibitor currently in late-phase clinical development as a potential treatment for Cushing’s disease. This study evaluated the inhibitory effect of osilodrostat on the pharmacokinetics of probe substrates of the cytochro...

Descripción completa

Detalles Bibliográficos
Autores principales: Armani, Sara, Ting, Lillian, Sauter, Nicholas, Darstein, Christelle, Tripathi, Anadya Prakash, Wang, Lai, Zhu, Bing, Gu, Helen, Chun, Dung Yu, Einolf, Heidi J, Kulkarni, Swarupa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394143/
https://www.ncbi.nlm.nih.gov/pubmed/28155129
http://dx.doi.org/10.1007/s40261-017-0497-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394143/
https://www.ncbi.nlm.nih.gov/pubmed/28155129
http://dx.doi.org/10.1007/s40261-017-0497-0

Ejemplares similares